Puma Biotechnology (PBYI) logo

Puma Biotechnology (PBYI) stock

Cancer care products , market cap $368M

$7.05
-0.98%

Why is PBYI down?

Down 16% on Nov 6, and still 28% under its Nov 5 close.

  • Its Nov 5 results: net income was $6.0M, from $8.8M a year before; adjusted net income was $8.0M, from $10.5M. It fell 16% on Nov 6.

Sources: Price history, Nov 6, 2026; Company release, Nov 5, 2026

Tell me next time PBYI moves

Free account, no card. An optional alert when PBYI moves or its score changes.Pro, $1 for a first month. An optional alert when PBYI moves or its score changes.Pro, 7 days free with a card. An optional alert when PBYI moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on PBYI →3 more reasons why PBYI fell on Nov 6, from its filings, with the timeline and its peers, for Pro members.

Why PBYI still beats the market over five years

Up 122% over the five years to Nov 20 while the S&P 500 rose 58%; down 16% on Nov 6.

5 reasons, from its filings, with the timeline, for Pro members.

Quality Score
2
Below Average
In its industry
#80of 273
Checks firing
1of 14
Trending up
From 52-week high
-38.7%
under its best in a year

PBYI's Quality Score rose 1 point on Fri, Nov 20, to 2. More shares traded than usual.

Follow PBYI's trial news. Pro members can get an alert when Puma Biotechnology files news, and see its trials, share raises, and its CEO's filings.

Get an alert when PBYI files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Key facts on PBYI

Key facts on PBYI
Holding it backMargin down 3.3 points
Latest filing10-Q, Nov 9 Filed its quarterly report (10-Q) for the quarter to Sep 30, 2026

PBYI in the news

What's next

Tue Dec 8: San Antonio Breast Cancer Symposium…Industry event · date confirmed.

PBYI catalysts

Coming up

After its last 4 reports it closed -6.9% on average, higher 2 of 4 times.

5 past catalysts since 2018, with sizes and sources, for Pro members.

What's next for PBYI

Its trials

A trial underway
ALISCA-Lung1Phase 2 · Recruiting · 120 people · main data estimated Oct 30, 2027 · NCT06095505

2 more trials, 23 filings, for Pro members.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: the amounts, and the share count against a year ago.

Insiders

Director Michael Patrick Miller sold 15,000 shares on Nov 11. 13 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Alan Auerbach’s 6 filings and quotes.

Get an alert when PBYI files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

Why PBYI scores 2

Below Averagefor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means

Well below its recent run. PBYI scores 2 today, against a median of 6 over its last 20 recorded sessions.

  • +1Chart checks 1 of 14 firing right now, one point each
  • −1Growth sales up 9% on the year, gross margin down 3.3 pointsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
  • Long-term trend adds
  • Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.

No effect today: Run-up, Size, Dilution, Volatility, Cash flow, Persistence, News, and Insider trades.

What every line is worth, and the reason behind it, on PBYI and every other stock.Get in free →See the top 3 →Start Pro

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:34 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How PBYI ranks in Biotech

PBYI is #80 of 273 by Quality Score.

How PBYI ranks in Biotech
RankStockQuality Score
80Puma Biotechnology (PBYI) logoPBYIPuma Biotechnology2

More in Biotech

When does PBYI report earnings, and what happens after?

Expected to report Thu Feb 25, after the close (in 96 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What PBYI reported on Nov 5, 2026

The quarter

Sales of $55.1M, 1% more than a year ago; a profit of $0.11 a share, from $0.17.

“Third quarter U.S. NERLYNX sales were positively impacted by increased year-over-year demand and were negatively impacted by higher than expected gross to net due to an increase in Medicaid and 340B sales, as well as a delay in sales to Puma’s ex-U.S. commercial partners that shifted from the third quarter to the fourth quarter”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

Where the quarter's sales came from
LineQ3
2026
Q2
2026
Q3
2025
By product
Productup 4.3%$54.1M98%$53.6M95%$51.9M95%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 9)

1 more line, for Pro members.

The outlook

No outlook figures read from this release.

In the company's words

  • “The third quarter and first nine months of 2026 included a $2.1 million reduction to royalty revenue as a change in accounting estimate, reflecting the receipt of new third-party market data confirming that the market share of generic versions of NERLYNX in China reached a specified threshold during the period.”

From its results filing (SEC filing · Nov 5)

2 more sentences, for Pro members.

The numbers

Market value
$368M
today
Sales
$232M
up 9.3% on the year
Free cash flow
$46.1M
last 12 months

Sales grew 0.3% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 5.1% a year over 5 years.

5 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on PBYI: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+3.2%+9.7%-15.6%
May 7Aug 6Nov 5
ReportedGapReaction5
days
Nov 5, 2026After close-15.3%-15.6%-17.3%
Aug 6, 2026After close+0.4%+9.7%+7.3%
May 7, 2026After close-1.2%+3.2%-1.0%

PBYI closed higher after 2 of its last 4 reports.

All 4 reports, and PBYI's Quality Score going into each

PBYI sales and profit by year

Sales and profit by year

Sales grew in three of the last seven years, to $228M in 2025. It made a profit in four of the eight years.

PBYI has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on PBYI, and all 14 on every stock.Get in free →See the top 3 →Start Pro

PBYI RSI on Nov 20: 24.5, below its 50-day and 200-day averages

Not scored

RSI 24.5, MACD below signal, below both averages. Not scored.

The deep dive on PBYI

11 more findings on PBYI, each with its source, for Pro members.

PBYI insider trades

One insider sold $121K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest:

SellMichael Patrick Miller$121KDirectorat $8.10 on Nov 11, filed Nov 13

PBYI's officers and directors

Officers and directors with a Form 4 in the last 12 months.

2 more officers and directors file at PBYI.

See insider trades by person

Which ETFs hold PBYI?

In ETFs: PBYI is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Puma Biotechnology

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

179 employeesLos Angeles, CApumabiotechnology.com

What Puma Biotechnology says it competes with

“The development and commercialization of new products to treat cancer is highly competitive.”

From its annual report, SEC filing · Feb 26, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on PBYI and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn PBYI's score around: 6 things
  • 2 more filings explained, a plain line each
  • Real-⁠time prices, no delay
BreakawayNov 13Michael Patrick Miller sold PBYI$121K at $8.10, filed Nov 13

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: PBYI's Quality Score is 2 (Below Average), #80 of 273 in Biotech. Insiders sold $121K in the last 6 months (Form 4).

What does PBYI's Quality Score say?

PBYI scores 2 today, which Breakaway calls Below Average. It is #80 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 16% on Nov 6, and still 28% under its Nov 5 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is PBYI's Quality Score?

PBYI scores 2 today, which Breakaway calls Below Average (0 to 5). That is #80 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PBYI's 2.

Are insiders buying PBYI?

One insider sold $121K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest is Michael Patrick Miller, Director, who sold $121K on Nov 11.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Puma Biotechnology: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.